American Association for Cancer Research
00085472can113917-sup-f6_78k.pdf (78.32 kB)

Supplementary Figure 6 from CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells

Download (78.32 kB)
journal contribution
posted on 2023-03-30, 21:13 authored by Marco Velasco-Velázquez, Xuanmao Jiao, Marisol De La Fuente, Timothy G. Pestell, Adam Ertel, Michael P. Lisanti, Richard G. Pestell

PDF file - 78K, Pulmonary tumors are enriched in CCR5+4 cells



The roles of the chemokine CCL5 and its receptor CCR5 in breast cancer progression remain unclear. Here, we conducted microarray analysis on 2,254 human breast cancer specimens and found increased expression of CCL5 and its receptor CCR5, but not CCR3, in the basal and HER-2 genetic subtypes. The subpopulation of human breast cancer cell lines found to express CCR5 displayed a functional response to CCL5. In addition, oncogene transformation induced CCR5 expression, and the subpopulation of cells that expressed functional CCR5 also displayed increased invasiveness. The CCR5 antagonists maraviroc or vicriviroc, developed to block CCR5 HIV coreceptor function, reduced in vitro invasion of basal breast cancer cells without affecting cell proliferation or viability, and maraviroc decreased pulmonary metastasis in a preclinical mouse model of breast cancer. Taken together, our findings provide evidence for the key role of CCL5/CCR5 in the invasiveness of basal breast cancer cells and suggest that CCR5 antagonists may be used as an adjuvant therapy to reduce the risk of metastasis in patients with the basal breast cancer subtype. Cancer Res; 72(15); 3839–50. ©2012 AACR.